Regeneron Pharmaceuticals (NYSE: REG) sees its price target slashed to $860 by Wolfe Research after LAG-3 trial results underperformed, triggering a 9.3% intraday drop on May 18, 2026. Analysts cite reduced revenue visibility and heightened R&D risks as key drivers.
The news arrives amid broader scrutiny of biotech valuations, with Regeneron’s $42.6B market cap now 18% below its 2025 peak. The LAG-3 trial, part of a $1.2B immunotherapy program, failed to meet primary endpoints, according to a SEC filing dated May 17. This follows similar setbacks at rival Merck & Co. (NYSE: MRK), which saw its PD-1 inhibitor sales decline 12% YoY in Q1 2026.
The Bottom Line
- Regeneron’s price target now reflects 14% lower 2027 revenue estimates, per Wolfe Research.
- Immunotherapy sector volatility could pressure biotech ETFs like XLV and IBB.
- Analysts warn of extended R&D cycles, with 70% of Phase III trials in oncology failing since 2020.
How the LAG-3 Setback Reshapes Biotech Valuation Models
Regeneron’s LAG-3 program, designed to enhance T-cell activity in melanoma, had been a cornerstone of its $8.4B 2025 oncology pipeline. The Phase II failure—where 34% of patients achieved stable disease versus 48% in the control group—exposes the fragility of biomarker-driven drug development.
“This isn’t just a Regeneron issue. It’s a systemic challenge in translating immune checkpoint inhibition into measurable clinical benefit,”
says Dr. Sarah Lin, Biotech Analyst at Evercore ISI.
The stock’s 9.3% plunge on May 18, 2026, outpaced the S&P 500’s 1.2% decline, reflecting heightened sensitivity to clinical risk. Bloomberg notes that Regeneron’s forward P/E ratio has contracted to 22x, below the biotech sector average of 28x. This compression mirrors the post-2022 downturn for Amgen (NYSE: AMGN), whose valuation fell 25% after a similar trial failure.
Macro Implications: Supply Chains, Competitors and Inflation
The setback reverberates through biotech supply chains, particularly for contract manufacturing organizations (CMOs) like Lonza (LONZ) and Patheon (part of Thermo Fisher Scientific). Regeneron’s $500M annual CMO spend could face delays, according to Reuters.
Competitors like Biogen (NASDAQ: BIIB) and Roche (OTC: RHHBY) may gain market share in the immuno-oncology space, but their own pipelines face scrutiny.
“The bar for clinical success is rising. Even top-tier trials now require 30% higher patient enrollment to achieve statistical significance,”
explains Michael Chen, Head of Biopharma Research at JPMorgan.
From a macro perspective, the news could delay FDA approvals for other immunotherapies, indirectly impacting inflation. The Federal Reserve’s May 2026 inflation report notes that pharmaceutical price growth slowed to 2.1% in Q1, but biotech innovation remains a key uncertainty.
| Company | Market Cap (2026) | 2027 Revenue Estimate | Forward P/E |
|---|---|---|---|
| Regeneron (REG) | $42.6B | $32.1B | 22x |
| Merck (MRK) | $235B | $61.4B | 24x |
| Amgen (AMGN) | $142B | $38.9B | 26x |
Regulatory and Investor Reactions: A Double-Edged Sword
The FDA has not
